Why did MOLN.SW stock fall sharply today?

The decline reflects a sell-off tied to pipeline and catalyst risk rather than a fresh earnings release. Heavy volume **50,587.00** amplified the move. Investors reacted to perceived clinical-readout uncertainty and sector sensitivity in Swiss biotech markets.

What is Meyka AI's forecast for MOLN.SW stock?

Meyka AI's forecast model projects a 12-month level around **CHF 2.35**, implying roughly **-29.89%** downside versus the CHF 3.35 close. Forecasts are model-based projections and not guarantees.

Is MOLN.SW stock undervalued versus sector peers?

On PB metrics MOLN.SW trades cheaper with price-to-book **1.31** versus the Healthcare average PB **4.72**. But negative EPS **-1.62** and trial risk justify a lower multiple compared with profitable sector peers.

What short-term technical levels should traders watch for MOLN.SW stock?

Watch intraday support near **CHF 3.35** and resistance at the 20-day band around **CHF 3.78**. The 50-day average is **CHF 3.51**; a clear break above it would ease near-term pressure.

CH Stocks

Market closed: MOLN.SW down 11.14% to CHF 3.35 on SIX: catalyst risk ahead

ByHuzaifa Zahoor March 14, 2026March 14, 2026

The market closed with MOLN.SW stock plunging 11.14% to CHF 3.35 on the SIX on 13 Mar 2026. Traders hit sell orders after a heavy session that posted 50,587.00 shares versus an average volume of 21,875.00. The drop followed no immediate company press release, leaving investors to focus on pipeline risks, recent clinical milestones, and valuation gaps against the Swiss Healthcare sector.